Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl
Neuropsychopharmacology
.
2024 Jan;49(1):319-320.
doi: 10.1038/s41386-023-01680-7.
Authors
Cassandra D Gipson
1
,
Justin C Strickland
2
Affiliations
1
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA. cdgips2@uky.edu.
2
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jstric14@jhmi.edu.
PMID:
37495677
PMCID:
PMC10700472
(available on
2025-01-01
)
DOI:
10.1038/s41386-023-01680-7
No abstract available
Publication types
News
MeSH terms
Analgesics, Opioid
Fentanyl*
Ketamine*
Public Health
Xylazine / pharmacology
Substances
Fentanyl
Xylazine
Ketamine
Analgesics, Opioid
Grants and funding
R01 DA046526/DA/NIDA NIH HHS/United States